Conferences & Symposia
2. Introduction to Heterogeneity of Treatment Effect (HTE)

After completing this lecture, you will be able to:

  • Describe current approaches and limitations to evidence-based medicine
  • Describe current approaches to detecting HTE in clinical trials
  • Describe the advantages of risk modeling approaches to HTE estimation.

Taught by David Kent, MD, MSc

Conferences & Symposia
3. Risk and Treatment Effects

After completing this lecture, you will be able to:

  • Describe ways we can estimate how to treat individual patients
  • Discuss general clinical situations that might be most appropriate for risk targeting.

Taught by Peter Rothwell, MD, PhD

Conferences & Symposia
4. Genetic Prediction of Common Diseases

After completing this lecture, you will be able to:

  • Explain how and when pharmacogenetics can work
  • Discuss methodological barriers to genomic prediction
  • Discuss the future of genomic prediction.

Taught by A. Cecile J.W. Janssens, PhD

Conferences & Symposia
5. Risk-Based Heterogeneity of Treatment Effect in 30 Large RCTs

After completing this lecture, you will be able to:

  • Explain why clinically significant risk heterogeneity is common in clinical trials
  • Describe why the typical patient is generally at lower risk than reflected by the trial summary results
  • Explain why a risk stratified approach to trial analysis may be the most clinically informative
  • Describe the implications of the study.

Taught by David Kent, MD, MSc

Conferences & Symposia
6. Person-Level HTE

After completing this lecture, you will be able to:

  • Explain person-level HTE in distinction to group-level HTE
  • Describe repeated period crossover studies
  • Discuss the results and the implications of the study.

Taught by: Issa J. Dahabreh, MD, MS

Conferences & Symposia
7. Discussion on Heterogeneity of Treatment Effects

After completing this lecture, you will be able to:

  • Describe the fundamental challenges in HTE
  • Explain the challenges of using estimated prognostic risk indices.

Taught by: Jessica Paulus, ScD, Ravi Varadhan, PhD, Douglas Altman, DSc, A.Cecile J.W. Janssens, PhD, and David Kent, MD, MSc

Conferences & Symposia
8. A Proposed Guideline for Reporting HTE in Large Randomized Clinical Trials

After completing this lecture, you will be able to:

  • Discuss the general credibility of subgroup analysis
  • Explain when individual patient characteristics should be part of a primary HTE analysis
  • Discuss when risk-based HTE should be part of a primary HTE analysis.

Taught by: Rod Hayward, MD

Conferences & Symposia
9. Panel Discussion

After completing this lecture, you will be able to:

  • Discuss the challenges of getting journal editors to agree on policies
  • Identify how guideline writing committees can make judgments about the value of observed magnitudes of treatment effects.

Discussants: Ewout Steyerberg, PhD; Douglas Altman, DSc; Robert Golub, MD; Rod Hayward, MD; David Kent, MD, MSc; and Walter Kernan, MD